Highest-materiality recent filing
Impact BioMedical amends merger deal with Dr Ashleys; extends deadline to July 1, 2026
Amendment adds 53,000 and 75,000 PubCo ordinary shares to be issued to DSS, Inc. at closing.
All eight director nominees elected with ~61.5M votes each; broker non-votes of ~2.7M.
DSS BioHealth converts Series A Preferred into 60.5M common shares of Impact BioMedical
DSS BioHealth Security converted its Series A Convertible Preferred Stock into 60,496,041 shares of common stock.
Impact BioMedical to issue 31.9M shares to DSS to settle $12M debt
Issued 31,939,778 shares of common stock to DSS Inc. to fully satisfy $12M revolving promissory note from March 2023.
Impact BioMedical (IBO) will merge with Dr Ashleys via a reverse merger; existing Impact shareholders receive 4.80% of the new PubCo's ordinary shares.
DSS withdraws from $13.2M debt conversion agreement; no shares issued
DSS withdrew from Debt Conversion Agreement, originally dated March 24, 2025.
Impact Biomedical settles $8.7M debt with 2.4M shares at $3.60/share
Debt conversion with DSS Inc. settles $8,697,142.80 of the $13,176,477.03 principal balance.
Impact Biomedical appoints Chan Heng Fai Ambrose to board of directors
Appointed March 11, 2025, effective same date; over 45 years financial/equity investment experience.
Impact Biomedical CEO presents investor slide deck on Jan 29, 2025; no details available
Slide package furnished as Exhibit 99.1 not included in filing text; no specifics provided.
Impact Biomedical furnishes investor presentation; no specific financial updates disclosed
COO Mark Suseck began delivering investor presentations on November 4, 2024.
Impact Biomedical enters three-year CEO employment agreement with Frank Heuszel
Term from Oct 3, 2024 to Oct 3, 2027; base salary $200K year 1, $250K years 2 and 3.
Impact Biomedical closes IPO of 1.5M shares at $3.00, net proceeds ~$3.76M
IPO of 1,500,000 common shares at $3.00 per share; net proceeds to company ~$3,764,500 after discounts and expenses.
Director Heng Fai Ambrose Chan resigns; Jason T. Grady appointed to board
Heng Fai Ambrose Chan resigned as director effective June 6, 2024, with no disagreement.
Impact BioMedical amends $12.86M promissory note with DSS; extends maturity to 2030
Funded principal balance increased to $12,859,328.60, including $1.23M in interest advances.
Exchanged 60,496,091 common shares held by majority shareholder DBH for 60,496,091 Series A Convertible Preferred shares.
On March 11, 2025, the Board of Directors of the Company appointed Mr. Chan Heng Fai Ambrose to serve as a Director of the Company, effective as of the same date.
Additionally on June 6, 2024, the Board of Directors of the Company appointed Jason T. Grady to serve as a Director of the Company, effective as of the same date.
On June 6, 2024, Heng Fai Ambrose Chan notified Impact Biomedical, Inc. (the “Company”) that he is resigning as a member of the Board of Directors of the Company, effective immediately.
Max materiality 1.00 · Median 0.65 · Most common event other_material